Business
IceCure Medical to Report First Quarter 2026 Financial and Operating Results on May 12, 2026
IceCure Medical Ltd. (Nasdaq: ICCM) ("IceCure", "IceCure Medical" or the "Company"), developer of minimally-invasive cryoablation technology that destroys tumors by freezing as an option to surgical tumor removal, today announced that it will issue a press release with its financial and operational results as of and for the three months ended March 31, 2026 before the Nasdaq Stock Market opens on Tuesday, May 12, 2026. The Company will also discuss such results and other corporate developments o
About this update from Icecure Medical Ltd.
[{"type":"text","content":"CAESAREA, Israel, May 6, 2026 /PRNewswire/ -- IceCure Medical Ltd. (Nasdaq: ICCM) ("IceCure", "IceCure Medical" or the "Company"), developer of minimally-invasive cryoablation technology that destroys tumors by freezing as an option to surgical tumor removal, today announced that it will issue a press release with its financial and operational results as of and for the three months ended March 31, 2026 before the Nasdaq Stock Market opens on Tuesday, May 12, 2026. The Company will also discuss such results and other corporate developments on a conference call at 11:00 a.m. EDT on the same day.","length":630,"tagName":"p"},{"type":"image","alt":"IceCure Medical Logo","displaySize":"","headline":null,"caption":"IceCure Medical Logo","className":"","disableSlideshowImg":false,"size":{"original":{"width":400,"height":200,"url":"https://media.zenfs.com/en/prnewswire.com/b733b9648e0c5c7b36e9d5bf48d042cc"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/0v6Nk71FF.FRuk4jS6_9xA--/YXBwaWQ9aGlnaGxhbmRlcjt3PTcwNTtoPTM1Mw--/https://media.zenfs.com/en/prnewswire.com/b733b9648e0c5c7b36e9d5bf48d042cc","width":400,"height":200}}},{"type":"text","content":" ","length":6,"tagName":"p"},{"type":"text","content":"Conference call & webcast info:Tuesday, May 12, 2026, at 11:00 am EDTUS: 1-888-407-2553Israel/International: +972-3-918-0696A live webcast will be available at: https://www.veidan-conferencing.com/icecure-investorsA recording of the webcast will be available at: ir.icecure-medical.com","length":299,"tagName":"p"},{"type":"text","content":"About IceCure MedicalIceCure Medical (Nasdaq: ICCM) develops and markets advanced liquid-nitrogen-based cryoablation therapy systems for the destruction of tumors (benign and cancerous) by freezing, with the primary focus areas being breast, kidney, bone and lung cancer. Its minimally invasive technology is a safe and effective option to surgical tumor removal that is easily performed in a relatively short procedure. The Company's flagship ProSense® system is marketed and sold worldwide for the indications cleared and approved to date including in the United States, Europe and Asia.","length":594,"tagName":"p"},{"type":"text","content":"Forward Looking StatementThis press release contains forward-looking statements within the meaning of the "safe har...